Welcome to our dedicated page for Creative Med Technology Hldgs news (Ticker: CELZ), a resource for investors and traders seeking the latest updates and insights on Creative Med Technology Hldgs stock.
Creative Medical Technology Holdings, Inc. develops regenerative medicine and immune-cell therapies as a clinical-stage biotechnology company trading under CELZ. Company news centers on CELZ-201, or olastrocel, an allogeneic/perinatal tissue-derived cell therapy evaluated in the FDA-cleared ADAPT trial for chronic lower back pain associated with degenerative disc disease, and on platform extensions such as Ultrasome for knee osteoarthritis.
Recurring updates also cover WHO International Nonproprietary Name activity for cell-therapy assets, CELZ-101 Treg immunotherapy work, and BioDefense Inc., a wholly owned subsidiary focused on burn pit exposure research using iPSC technology, AI-enabled molecular modeling, and regenerative countermeasure development.
Creative Medical (NASDAQ: CELZ) issued a mid-year 2026 update highlighting progress across regenerative medicine and AI-enabled biodefense programs. Olastrocel (CELZ-201) showed statistically significant 180-day improvements in chronic lower back pain, with an FDA-cleared ADAPT trial expansion. Ultrasome™ achieved a 93% responder rate in an osteoarthritis pilot. The CELZ-Biodefense burn pit initiative received national regulatory approval and is scaling an AI-driven Toxic Exposure Atlas™, targeting at least 1,000 veterans. Management emphasizes lean operations, non-dilutive funding where possible, and aligning any future capital raises with value-creating milestones.
Creative Medical Technology (Nasdaq: CELZ) entered agreements for the immediate exercise of up to 2,790,340 warrants at a reduced exercise price of $1.60 per share, generating expected gross proceeds of about $4.5 million before fees.
The company will issue new unregistered warrants for up to 5,580,680 shares at $1.60, exercisable for five years after shareholder approval. Closing is expected on June 30, 2026, with net proceeds intended for working capital and general corporate purposes.
Creative Medical Technology (NASDAQ: CELZ) received FDA clearance to expand its ADAPT trial of Olastrocel (CELZ-201) for chronic lower back pain from degenerative disc disease.
The new 15-patient, under-90 mg morphine-equivalent cohort is >85% enrolled, uses an AI monitoring platform, builds on positive 180-day efficacy and safety data, and supports Phase 3 planning with existing resources.
Creative Medical Technology (NASDAQ: CELZ) advanced Project PHOENIX into a nationwide, AI-driven virtual data collection phase for U.S. veterans exposed to burn pits and toxic hazards.
The CELZ-Biodefense platform targets at least 1,000 veterans, integrates multi-omics and AI, and is expected to use existing infrastructure without additional fundraising.
Creative Medical Technology Holdings (NASDAQ: CELZ) reported pilot results for Ultrasome™, a cell-free therapy derived from GMP-produced CELZ-201, showing a 93% response rate for clinically meaningful pain and mobility improvement in knee osteoarthritis and no serious adverse events.
The program links CELZ-201 to scalable, off-the-shelf cell-free manufacturing and the company plans expanded clinical work, additional data generation, and evaluation of commercialization and partnership pathways.
Creative Medical Technology Holdings (NASDAQ: CELZ) announced a second WHO International Nonproprietary Name (INN) milestone: the WHO published the proposed INN etaroleucel for CELZ-101 in Proposed INN List 134 following the 80th INN Consultation.
The name is entering the formal objection period prior to final confirmation. This follows prior proposed INN olastrocel for CELZ-201 in Proposed INN List 133, reinforcing multi-program regulatory positioning.
Creative Medical Technology Holdings (NASDAQ: CELZ) reported positive interim 180-day ADAPT trial data for CELZ-201 (Olastrocel) in chronic lower back pain associated with degenerative disc disease on January 13, 2026. The interim analysis showed mean ODI% improvement −15.3 points (p=0.0003) and mean pain reduction −3.9 points (p<0.00005); ~79% of patients achieved clinically meaningful functional and pain improvements. An independent DSMB found no serious adverse events and no treatment-related safety signals. The company says it will pursue late-stage regulatory engagement, strategic partnerships, and commercialization planning pending final data.
Creative Medical Technology Holdings (NASDAQ: CELZ) announced regulatory approval on January 6, 2026 for its BioDefense Inc. Burn Pit Initiative, allowing the program to proceed nationally to collect expanded molecular and cellular data from veterans affected by burn pit exposure.
The company said no additional fundraising is required; the program will be funded using existing partnerships (including Greenstone Biosciences), internal infrastructure, and prior vendor relationships to support AI-driven molecular modeling, iPSC development, and regenerative countermeasure work.
Creative Medical Technology (NASDAQ: CELZ) announced on Dec 17, 2025 that it has completed patient enrollment in the FDA-cleared ADAPT clinical trial evaluating CELZ-201 (Olastrocel) for chronic lower back pain associated with degenerative disc disease. A prior independent DSMB safety review confirmed a favorable safety profile with no significant adverse events. With enrollment finished, the program moves to follow-up and data analysis as the company advances toward topline safety and efficacy readouts and late-stage development planning.
Creative Medical (NASDAQ: CELZ) announced on Dec 2, 2025 that the World Health Organization approved olastrocel as the International Non‑Proprietary Name (INN) for the active cellular substance in its lead allogeneic cell therapy CELZ‑201 (AlloStem).
The INN gives a globally standardized scientific name to the asset, aiding regulatory and clinical clarity, pharmacovigilance, labeling, and international development. Company leadership said the milestone supports global advancement and complements the program’s FDA Fast Track designation in degenerative disc disease. Olastrocel is being developed as an off‑the‑shelf perinatal‑tissue cell therapy for chronic lower back pain/DDD, new‑onset type 1 diabetes, and biodefense‑related indications.